Skip to main content

First patient dosed in Phase 2 Clinical Trial of OTX-DED

Twitter LinkedIn Email

About
Pipeline
- OTX-TIC (travoprost implant)
- OTX-TKI (tyrosine kinase inhibitor implant)
Products
- DEXTENZA^®
- ReSure^® Sealant
Investors
Careers
Search

News

Page not found

Sorry, the page you were looking for doesn’t exist or has been moved.

Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Phone: 1-877-628-8998

© 2021 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA and ReSure are trademarks of Ocular Therapeutix, Inc. PP-US-OTX-0004

Privacy Policy | Terms of Use

The use of this Site is governed by its Terms of Use. The information contained in this Site is for informational purposes only. It is not a substitute for professional medical advice and should not be used to diagnose or treat any medical or health condition.

The contents of this Site are subject to change without notice. Ocular Therapeutix may modify and/or discontinue operation of all or portions of this Site at any time at its sole discretion without notice, and assumes no responsibility to update this Site. Ocular Therapeutix makes no representations or warranties with respect to the use of this Site or any information obtained herein.

Top